- 學位論文
生物功能化技術在檢測生物分子上的應用 －以VEGF與CYFRA21-1為例－
Application of Biofunctionalization Techniques in the Detection of Biomolecules: A Case Study on VEGF and CYFRA21-1
摘要
癌症是全球死亡的主要原因之一，使得血管內皮細胞生長因子(VEGF)及細胞角質蛋白19基因片段21-1 (CYFRA21-1)的檢測對於癌症的診斷有著極大的重要性。本研究以常見的生物晶片改質材料結合指叉電極，提供Anti-body/EDC-NHS/MUA和Anti-body/GA/APTES兩種不同的生物功能化方法，以線性掃描伏安法 (LSV) 檢測CYFRA21-1及VEGF，並透過繪圖分析軟體Origin進行數據分析，探討CYFRA21-1和VEGF在兩種不同生物功能化製程中的濃度檢測靈敏度，以驗證其在生物傳感器應用中的可行性。結果顯示，在VEGF的檢測中Anti-body/EDC-NHS/MUA和Anti-body/GA/APTES製程的R2值分別為0.99731及0.9705； 在CYFRA21-1的檢測中則為0.99197及0.99057。靈敏度方面，Anti-body/GA/APTES製程在兩者的檢測中皆略高於Anti-body/EDC-NHS/MUA製程。這些製程中的線性度和靈敏度都顯示出良好的性能，表現出其在生物傳感器開發中的潛力和應用價值，為生物傳感器技術在臨床診斷中的進一步發展提供了實用的數據基礎。
並列摘要
Cancer is one of the leading causes of death worldwide, making the detection of Vascular Endothelial Growth Factor (VEGF) and Cytokeratin 19 Fragment 21-1 (CYFRA21-1) crucial for cancer diagnosis. This study combines commonly used biochip modification materials with interdigitated electrodes, providing two different biofunctionalization methods: Anti-body/EDC-NHS/MUA and Anti-body/GA/APTES. Linear Sweep Voltammetry (LSV) is employed to detect CYFRA21-1 and VEGF, and data analysis is performed using the graphing software Origin to investigate the sensitivity of CYFRA21-1 and VEGF concentration detection in these two different biofunctionalization processes, validating their feasibility in biosensor applications. The results show that in VEGF detection, the R2 values of the Anti-body/EDC-NHS/MUA and Anti-body/GA/APTES processes are 0.99731 and 0.9705, respectively; in CYFRA21-1 detection, the R2 values are 0.99197 and 0.99057, respectively. In terms of sensitivity, the Anti-body/GA/APTES process is slightly higher than the Anti-body/EDC-NHS/MUA process in both detections. The linearity and sensitivity in these processes demonstrate good performance, indicating their potential and application value in biosensor development, providing practical data for the further advancement of biosensor technology in clinical diagnostics.